What kind of cancer received the first fda approval for keytruda?

What Type of Cancer Was First Treated by Keytruda?

When Keytruda, a checkpoint inhibitor drug, received its first FDA approval, it was for the treatment of unresectable or metastatic melanoma.[1]

In November 2014, the FDA granted accelerated approval to Keytruda (pembrolizumab) for the treatment of patients with unresectable or metastatic melanoma, a type of skin cancer. The approval was based on results from a clinical trial, which showed that Keytruda significantly improved overall survival compared to the standard treatment, ipilimumab.[1]

Why Was Keytruda a Breakthrough in Cancer Treatment?

The approval of Keytruda marked a significant advancement in cancer treatment, as it was the first time a drug targeting the PD-1 protein had been approved for the treatment of melanoma. This drug works by enhancing the body's own immune system to fight cancer. By targeting the PD-1 protein, Keytruda unlocks an immune "brake" on the immune system, allowing it to more effectively target and kill cancer cells.[2]

How Has Keytruda's Use Expanded Over Time?

Since its initial approval, Keytruda has received additional approvals for various other types of cancer, including non-small cell lung cancer, head and neck cancer, bladder cancer, Hodgkin lymphoma, hepatocellular carcinoma, and microsatellite instability-high (MSI-H) cancers. Today, Keytruda is used to treat a range of cancer types and has become a cornerstone in the treatment of certain cancer types.[3]

Sources:

[1] https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-pembrolizumab-treatment-melanoma
[2] https://www.drugpatentwatch.com/patent/US10284443
[3] https://www.keytruda.com/